Detection of Genetic Translocations in Lymphoma Using Fluorescence In Situ Hybridization

Reichard, Kaaren K.; Robinett, Sheldon

doi:10.1007/978-1-62703-357-2_12

Cited by 3 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Complete and accurate lymphoma staging is essential to determine the extent of disease involvement, as it affects the prognosis and appropriate treatment. However, the complexity of the bone marrow evaluation process has led to heterogeneity in the results obtained by different methods, and this is an obstacle to the clinical trial studies of lymphoma patients (2)(3)(4)(5)(6)(7)(8)(9)(10). Despite the continuous development of assistive devices used in the laboratory to assess the malignancy of lymphoma in the last decade, the study of bone marrow involvement in malignant lymphomas is still valuable and bilateral biopsy is the standard method.…”

Section: Introductionmentioning

confidence: 99%

Correlation of flow cytometry and bone marrow biopsy in marrow involvement of lymphoma patients

Nematollahi,

Mohammadi Jazi,

Forouzandeh

2023

J Ren Endocrinol

View full text Add to dashboard Cite

Introduction: Non-Hodgkin’s lymphomas (NHLs) are hematolymphoid malignancies. Bone marrow biopsy (BMB) is performed for staging. BMB findings are an important indicator of prognosis and treatment planning. In this study, we compared flow cytometry and BMB in marrow involvement of lymphoma patients. Objectives: This study aimed to compare the frequency of involvement in bone marrow in flow cytometry and biopsy, compare the frequency of involvement in bone marrow in flow cytometry based on gender, compare frequency of bone marrow involvement in biopsy based on gender, compare mean age between two groups with bone marrow involvement and without bone marrow involvement in biopsy, compare mean age between two groups struggling with bone marrow involvement and without bone marrow involvement in flow cytometry, and compare mean ages between all genders struggling with bone marrow involvement and without bone marrow involvement in flow cytometry and biopsy. Patients and Methods: This study was cross-sectional, and the population included all patients affected by NHL, which bone marrow flow cytometry and biopsy performed for disease staging referred to Seyed Al-Shohada hospital affiliated with Isfahan University of medical sciences during 2016-2020. Four color flow cytometry devices (PARTEC CyFlow Space, Germany) with EXBIO antibody kits (Spain) were used. Results: In this study, the number of samples was 107, of which 68 (63.6%) were male, and the mean (standard deviation) of the total age was 40.87 (18.98) years. All samples were diagnosed as lymphoma and were examined by bone marrow flow cytometry and biopsy. Flow cytometry frequency of bone marrow involvement was 14 (13.1%), and biopsy frequency of bone marrow involvement was 22 (20.6%). In 97 cases (90.6%), the diagnosis of both methods was the same. Nine patients (8.4%) had bone marrow involvement in biopsy only, and one case (1%) had bone marrow involvement in flow cytometry only. As a result, bone marrow involvement in patients with lymphoma who participated in this project is about 21.5%. Conclusion: We concluded that evaluation of bone marrow involvement using combined methods is more efficient than biopsy or flow cytometry alone. We also recommended physicians use both methods at the same time.

show abstract

Section: Introductionmentioning

confidence: 99%

Correlation of flow cytometry and bone marrow biopsy in marrow involvement of lymphoma patients

Nematollahi,

Mohammadi Jazi,

Forouzandeh

2023

J Ren Endocrinol

View full text Add to dashboard Cite

show abstract

“…In addition to biopsies, flow cytometry and bone marrow aspiration may be used to help detect lymphoma [21, 22]. Upon diagnosis of lymphoma, patients will undergo a series of medical tests to examine further the specific disease, which may include immunohistochemistry, cytogenetic analysis, immunophenotyping, and fluorescence in situ hybridization [23–25]. …”

Section: Introductionmentioning

confidence: 99%

Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies

England

Cai

2016

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Lymphoma is a complex disease that arises from cells of the immune system with an intricate pathology. While lymphoma may be classified as Hodgkin or non-Hodgkin, each type of tumor is genetically and phenotypically different and highly invasive tissue biopsies are the only method to investigate these differences. Noninvasive imaging strategies, such as immunoPET, can provide a vital insight into disease staging, monitoring treatment response in patients, and dose planning in radioimmunotherapy. ImmunoPET imaging with radiolabeled antibody-based tracers may also assist physicians in optimizing treatment strategies and enhancing patient stratification. Currently, there are two common biomarkers for molecular imaging of lymphoma, CD20 and CD30, both of which have been considered for investigation in preclinical imaging studies. In this review, we examine the current status of both preclinical and clinical imaging of lymphoma using radiolabeled antibodies. Additionally, we briefly investigate the role of radiolabeled antibodies in lymphoma therapy. As radiolabeled antibodies play critical roles in both imaging and therapy of lymphoma, the development of novel antibodies and the discovery of new biomarkers may greatly affect lymphoma imaging and therapy in the future.

show abstract

“…Complete and accurate staging of non-Hodgkin lymphoma (NHL) is essential in determining the extent of disease, which may affect both the prognosis and treatment strategies [ 1 , 2 , 3 , 4 , 5 ]. Although there has been a continual growth in the number of ancillary tools that can be used in the laboratory to evaluate malignant lymphoma over the last decade [ 6 , 7 , 8 , 9 ], evaluation of bone marrow involvement of malignant lymphoma is still an important aspect, and bilateral trephine biopsies have been regarded as the standard method [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Bone Marrow Flow Cytometry in Staging of Patients With B-cell Non-Hodgkin Lymphoma

et al. 2015

View full text Add to dashboard Cite

BackgroundBone marrow biopsies are routinely performed for staging patients with B-cell non-Hodgkin lymphoma (NHL). In addition to histomorphological studies, ancillary tools may be needed for accurate diagnosis. We investigated the clinical utility of multiparameter flow cytometric examination of bone marrow aspirates.MethodsA total of 248 bone marrow specimens from 232 patients diagnosed with B-cell NHL were examined. Monoclonal antibodies directed against CD19, CD20, CD10 (or CD5), and κ and λ immunoglobulins were used. Multi-stage sequential gating was performed to select specific cells of interest, and the results were compared with bone marrow histology.ResultsThe concordance rate between histomorphology and flow cytometry was 91.5% (n=227). Eight cases (3.2%) were detected by flow cytometry alone and were missed by histomorphology analysis, and 6 of these 8 cases showed minimal bone marrow involvement (0.09-2.2%). The diagnosis in these cases included large cell lymphoma (n=3), mantle cell lymphoma (n=3), and mucosa-associated lymphoid tissue (MALT) lymphoma (n=2). Thirteen cases were histopathologically positive and immunophenotypically negative, and the diagnoses in these cases included diffuse large cell lymphoma (n=7), T-cell/histiocyte-rich large B-cell lymphoma (n=2), anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma (n=1), follicular lymphoma (n=1), MALT lymphoma (n=1), and unclassifiable lymphoma (n=1).ConclusionsMulti-color flow cytometry can be a useful method for assessing bone marrow in staging NHL and also plays a complementary role, especially in detecting small numbers of lymphoma cells.

show abstract

Detection of Genetic Translocations in Lymphoma Using Fluorescence In Situ Hybridization

Cited by 3 publications

References 8 publications

Correlation of flow cytometry and bone marrow biopsy in marrow involvement of lymphoma patients

Correlation of flow cytometry and bone marrow biopsy in marrow involvement of lymphoma patients

Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies

Bone Marrow Flow Cytometry in Staging of Patients With B-cell Non-Hodgkin Lymphoma

Contact Info

Product

Resources

About